Liquid Biopsy & Circulating Tumor DNA (ctDNA) Testing
Minimally invasive blood test detecting cell-free circulating tumor DNA fragments to identify resistance mutations and minimal residual disease (MRD).
Clinical Overview & Diagnostic Rationale
Liquid biopsy isolates fragments of tumor DNA shed into peripheral bloodstream. It offers a non-invasive tool to monitor tumor genetic evolution, detect emergent drug resistance mutations (e.g. EGFR T790M/C797S), and measure minimal residual disease.
Primary Indications & Clinical Scenarios
Blood sample collected into specialized Streck ctDNA preservative blood collection tubes.
Medical Disclaimer: This information is educational and does not replace a consultation with your doctor. Specific diagnostic protocols are individualized following clinical examination at the clinic.
Questions About Your Liquid Biopsy & Circulating Tumor DNA (ctDNA) Testing?
Looking for clear guidance regarding Liquid Biopsy & Circulating Tumor DNA (ctDNA) Testing preparation, scan report terminology, fasting protocols, or diagnostic timelines? Consult Dr. Narendra Rathore's OncoAssist Clinical Guide. Developed for patient FAQs, radiation therapy precautions, chemotherapy guidance, and OPD appointment logistics.
Dr. Narendra Rathore
MBBS, MD (Radiotherapy)Professor and Head of Department, Radiation Oncology
RNT Medical College, Udaipur, Udaipur, Rajasthan
Senior Radiation Oncologist providing clinical evaluations, radiation therapy (3D-CRT/IMRT), chemotherapy planning, and supportive cancer care at RNT Medical College & MB Hospital, Udaipur.
Schedule Your OPD Consultation
All oncology consultations, scan reviews, and treatment planning with Dr. Narendra Rathore are conducted strictly in-person at MB Hospital campus, Udaipur.
- Original Biopsy & Histopathology Reports
- CT / MRI / PET Scan Films & DICOM CDs
- Prior Doctor Prescriptions & Chemotherapy Records
- Patient Photo ID & Scheme Card (RGHS / Chiranjeevi)